Zhejiang Huahai Pharmaceutical Co Ltd
600521
Company Profile
Business description
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company’s products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
Contact
Xunqiao
Zhejiang Province
Linhai317024
CHNT: +86 57685010288
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
9,065
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,504.67 | 61.07 | -0.13% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,879.18 | 38.23 | 0.18% |
| Nikkei 225 | 53,413.68 | 290.19 | 0.55% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,582.69 | 7.37 | 0.11% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |